Snakebites are a neglected tropical disease with a high Introduction: burden in South and South-East Asia and sub-Saharan Africa. In 2019, the World Health Organization (WHO) released a roadmap which aims for a 50% reduction in death and disability due to snakebite globally by 2030. It is estimated that India has the highest number of snakebite deaths in the world.
Background
Snakebites are a neglected tropical disease, with considerable burden in South Asia, Southeast Asia, and sub-Saharan Africa 1 . They are known to affect rural, indigenous and economically disempowered communities who lack political voice [2] [3] [4] . A modelling study using data on venomous snake distribution, health-care access, and availability of snake anti-venom, estimated that globally 146.70 million people live in snakebite prone areas lacking quality health-care provisions 5 . However, broad consensus is that these numbers are underestimates as many affected by snakebite are 'out-of-reach' of the formal health systems 6, 7 . Snakebite envenomation also causes longterm health effects, and is believed to have high social and economic impacts in affected communities 6, 8, 9 . Morbidity and socio-economic impact of snakebite is not well understood and remains under-researched globally 9,10 .
In 2018, recognising the public health impact of snakebite on vulnerable communities the World Health Assembly (WHA) passed a resolution to address the burden of snakebite 4 . Earlier in 2019 the World Health Organization (WHO) released a roadmap which aims to halve by 2030 the death and disability due to snakebite globally 11 . The WHO strategy rests on four pillars of action: empowering and engaging communities; ensuring safe, effective treatment; strengthening health systems; and increasing partnerships, coordination and resource usage through collaborations 11 .
More than a third of the global deaths, about 46,000 annually, are estimated to occur in India 12 with not much known about other aspects of burden 7 or risk factors in the country. Understanding the epidemiology of snakebites (in terms of incidence/prevalence of bites and envenoming, mortality, morbidity and risk factors) at the national and subnational level together with economic costs and health facility burden is critical for developing strategies, plans and programs to address the burden of snakebite. There are no systematic reviews on the burden and risk factors for snakebite in India, although evidence synthesis on burden and impact has been done for other countries or regions [13] [14] [15] [16] . The current article provides the protocol for a systematic review on the burden and risk factors for snakebite in India.
Objectives
To synthesize evidence on the burden (incidence/ prevalence, mortality, morbidity, health facility and economic), and risk factors for snakebite in India
Research questions
1. What is the burden (incidence/ prevalence, mortality, morbidity, health facility, and economic) of snakebite in India nationally and sub-nationally?
2. What are the risk factors related to snakebite (bite, envenomation, death, adverse outcomes) in India?
Protocol and registration
The objectives, inclusion criteria and methods of analysis for this systematic review are specified in advance and documented in this a priori protocol.
Eligibility criteria
The systematic review consists of two distinct evidence syntheses -burden (incidence/prevalence, mortality, morbidity, health facility and economic); and risk factors for snakebite (bite, envenomation, death, adverse outcomes). Synthesis of evidence for each domain will be conducted and reported separately in alignment with recent Cochrane guidelines 17 .
Eligibility criteria for evidence synthesis on the burden of snakebite in India We will include studies that meet the following criteria:
• Population -involving human participants from India, irrespective of age, gender or any other characteristics.
• Condition -snakebite irrespective of how it is diagnosed, measured or confirmed.
• Settingfacility or community-based studies; autopsybased studies will be included for understanding aspects of burden, as relevant.
• Burden Outcomes -° Incidence/ prevalence-incidence rate of snakebite or snakebite envenoming (i.e. clinical envenoming) (population or age-specific) from community-based studies only; prevalence rate of snakebite or snakebite envenoming from community-based, autopsy-based and facility-based studies;° ○ cross-sectional studies (analytical)
• There will be no restriction by year of publication or language.
Eligibility criteria for evidence synthesis of risk factors for snakebite in India
We will include studies that meet the following criteria:
• Population -involving human participants with snakebite or at-risk of snakebite from India. We will not include hospital based forensic-autopsy studies for understanding risk factors.
• Setting: facility or community-based studies; autopsybased studies will be excluded as they cannot give data on risk factors.
• Risk factors of interest and related outcomes -No a priori list of risk factors is listed as the scope of the evidence synthesis is broad. We will include any risk factor related to following outcomes ○ incidence of snakebite, snakebite envenomation (clinical illness), death due to snakebite from community-based studies (reported in terms of relative risks (RR), odds ratios (OR), hazard ratios (HR), standardized incidence ratios (SIR) or a standardized mortality ratios (SMR); adjusted or otherwise) ○ snakebite envenomation (clinical illness), death due to snakebite, adverse outcome (as defined by study authors) from facility-based studies (reported in terms of relative risks (RR), odds ratios (OR), hazard ratios (HR), standardized incidence ratios (SIR) or a standardized mortality ratios (SMR); adjusted or otherwise)
• Study design -We will include the following study designs:
○ cohort studies (prospective and retrospective)
○ case-control studies ○ cross-sectional studies (analytical)
We will not include risk-modelling studies as they are not within the scope of the current evidence synthesis.
Information sources and search strategy Electronic databases
We will search the following electronic databases for eligible studies using adaptions of the MEDLINE search strategy developed for this purpose (see extended data 18 ):
Searching other resources
We will hand-search IndMed (a bibliographic database covering prominent peer reviewed Indian biomedical journals), conference abstracts (including but not limited to Indian Public Health Association Conference -IPHACON, Annual Conference of the Toxinological Society of India-TSICON, Annual National Conference of Indian Society Of Toxicology -TOXOCON: as available) and contact researchers of repute in India to identify more studies. We will also hand search vital statistics data, government reports, population surveys or white papers which have reported on the burden and/or risk factors for snakebite specifically in relevant websites. We will also hand search the reference lists of all included studies found by other methods to retrieve additional records.
Study selection
Two review authors will independently assess the eligibility of primary studies based on titles and/or abstracts in the first phase. We will then acquire the full text of all papers identified as potentially relevant by at least one review author. Two review authors will then assess these papers independently and classify them into four categories -included for burden; included for risk factors; included for both burden and risk factors; excluded. We will resolve disagreements, by discussion with a third reviewer acting as an arbiter. We will attempt to contact study authors for further information, if necessary.
Data management
We will extract data using a standardised data extraction protocol, developed by adding extra data elements to the JBI recommended minimum standards for data extraction for prevalence, incidence and risk factor systematic reviews 19, 20 . Data management will be done using the Joanna Briggs Institute-The System for the Unified Management, Assessment and Review of Information (SUMARI).
Quality of included studies
We will appraise the quality of the included studies by using the JBI quality assessment tools for cohort, analytical cross-sectional and case-control studies 19,20 .
Synthesis of results
Synthesis methods for evidence synthesis on the burden of snakebite in India Data from facility based and community-based studies will be synthesised and reported separately, except in the case of studies which have conducted both concurrently.
We will narratively summarise the results of the study. An equity lens will be applied to understand incidence/prevalence, mortality and morbidity equity issues in a granular fashion. We will use the PROGRESS plus framework 21 for this purpose and extract and synthesise disaggregated data, if available on the framework parameters (PROGRESS-Plus -Place of residence; Race/tribal people; Occupation; Gender/sex; Religion; Education; Socioeconomic status; Social capital; and "Plus" to indicate other possible equity factors which might affect the outcomes of interest in relation to snakebite). We will assess patterns in the data through tabulation of results.
We do not intend to conduct a meta-analysis or any additional quantitative analysis and will present data as reported. In general heterogeneity between studies on prevalence and incidence is known to be common, rendering meta-analysis inappropriate 19 . In addition, snakebite as a condition is known to be localised in nature. As such, pooling of data from heterogenous studies into one pooled estimate will not reflect the variability in the burden of the condition at sub-national and local levels. The phenomenon of diluting the burden of snakebite by pooling of specific local data into national snakebite incident rate data has been previously recognised and been described as the 'tyranny of mean values' 6 .
Synthesis methods for evidence synthesis of risk factors for snakebite in India
Analysis for each individual risk-factor outcome pair will be conducted separately. If appropriate, meta-analyses will be conducted as per the JBI Guidelines 20 . A random or fixed effects model with a 95% CI will be chosen for the meta-analysis based on the presence of heterogeneity assessed by Tau-squared, Cochran's Q test and Chi-squared (p > 0.05) tests 20 . We plan to conduct sub-group analyses for the following, if enough studies are found:
• Study design • Setting (community based; facility based)
• Sex/gender (male; female; other)
• Age groups: Children (less than 10 years), adolescent (11-19 years), young adults (20-24 years)
• Tribal / non-tribal people
• Occupation (agricultural/plantation workers or farmers, and fishermen) Sensitivity analyses will be conducted, as appropriate, and if enough studies are available, to assess robustness of results but we are not specifying any a priori sensitivity analyses in the protocol phase. We will generate a funnel plot to assess publication bias if there are more than nine studies included in a specific meta-analysis. Funnel plot asymmetry will be tested by statistical tests (Egger test, Begg test, Harbord test) as appropriate.
Dissemination of information
We will publish the results of this review and will make the data accessible openly in re-usable format. The data will also be disseminated through evidence summaries and policy briefs to stakeholders in governments, public institutions and communities.
Study status
The search, screening and subsequent steps will be undertaken after the protocol completes peer-review.
Data availability
Underlying data All data underlying the results are available as part of the article and no additional source data are required. The objective related to Burden and risk factors are clumped with incidence/prevalence, mortality and morbidity and envenomation; may be provided in more elaboration specially risk factor because adverse outcome and death is not risk factor for envenomation. The authors have reported their work appropriately according to the PRISMA-P checklist.
Extended data
Eligibility criteria: It should be made clear that all or part of the eligibility criteria will need to be fulfilled. Risk factor is not properly addressed here and authors has no plan for risk modelling. Risk variables are not clear too. I think more emphasis was given on burden. So more clarification and clear objective about risk factor should be mentioned.
Condition: 'irrespective of how it was diagnosed'-is it, that venomous and non venomous bites will be grouped together which will cause problem in interpretation of the results. Dataset search strategy: It can also include venomous and antivenom as we consider economic burden .
Synthesis of result:
It is not unusual to get heterogeneous result due to regional variability and low impact article. So how the authors analyse this heterogeneity should be mentioned.
Health facility burden (page 3): Usually all/most of the patients of snakebite present at the emergency department unless manifested as chronic condition. Definition/clarity is required on 'specialist', 'higher facility', 'compartmental syndrome', 'long term rehabilitation support'. How uniformity among the investigators on decision for ventilatory support, dialysis, blood transfusion will be interpreted. How the individual component of data will be collected.
Study design (page 4): It would not be wise to have a study having no restriction of 'year of publication' to see the burden and risk factors which may change over time.
Risk factors: a list may be developed. 2 bullet is not clear-snakebite irrespective of envenomation may also be admitted, so admission does not necessarily mean envenomation. nd Risk factors: a list may be developed. 2 bullet is not clear-snakebite irrespective of envenomation may also be admitted, so admission does not necessarily mean envenomation. Searching other sources: how the authors will identify 'researchers of repute'.
Is the rationale for, and objectives of, the study clearly described? Yes

Is the study design appropriate for the research question? Yes
Are sufficient details of the methods provided to allow replication by others? Partly
Are the datasets clearly presented in a useable and accessible format? Yes
No competing interests were disclosed.
1) Page 4 -Eligibility criteria for risk factors for snakebite in India:Can you please elaborate as to why risk modelling studies are not within scope of this systematic review? The scope of this review is as I understood broad, summarizing all the evidence on burden and risk factors for snakebite. To my understanding, risk modelling studies may contribute to the scope as set by the authors.
2) Dataset search strategy: I would search for "envenom*" instead of "envenomation*". This will make sure you also find records that use the term "snake envenoming" instead of "snake envenomation".
3) Page 5 -Synthesis methods for evidence synthesis on the burden of snakebite in India: Though I agree it may be misleading to pool data from different diverse regions into one national summary, it may be worthwhile to consider whether combining findings from studies from the same (or similar) regions is possible. Therefore I'm not sure whether a priori excluding the possibility of a meta-analysis for incidence/prevalence data is the best option here.
4) Page 5 -Synthesis methods for evidence synthesis of risk factors for snakebite in India:
It is generally not advisable to choose the type of meta-analysis method (fixed or random) a posteriori, based on the observed level of heterogeneity (JBI Handbook section 5.5.8.2 & Cochrane Handbook section 10.10.4.1 ). Rather, one should consider the underlying assumptions of the two models and decide a priori which method would likely be the most appropriate in relation to the expected type of data. Please address this issue.
5) Page 5 -Synthesis of results:
In case meta-analyses are considered inappropriate, one will need to synthesize the data in another way. Please provide a method for doing this. The guidance by Campbell et al. and Chapter 12 of the Cochrane Handbook may provide valuable input for this.
6) Page 5 -Synthesis of results:
In case a meta-analysis can be performed, it is not unlikely that you will encounter statistically heterogeneous results. Please elaborate on how you will assess heterogeneity (i.e. what will you consider a heterogenous result?). Guidance on this can be found in Chapter 10.10 of the Cochrane Handbook . 7) PRISMA-P Item 12: Although the authors state "a standardised data extraction protocol, developed by adding extra data elements to the JBI recommended minimum standards for data extraction for prevalence, incidence and risk factor systematic reviews" will be used, it is not clear which items the authors will extract. It would be transparent to add an empty copy of this data extraction sheet, to be clear about which data items will be extracted.
8) PRISMA-P Item 14:
The authors need to clarify how they will use the risk of bias assessment during data synthesis. 9) PRISMA-P Item 17: I disagree that assessment of the body of evidence is not applicable. Several studies will contribute to outcomes, therefore it is useful to assess our overall confidence in the evidence gathered from different studies. I'm not saying the authors should definitely use the GRADE approach for this, but being transparent in how the overall strength of the body of evidence will be evaluated is necessary.
